Sang-Moo Kang

Dr. Sang-Moo Kang

Georgia State University, Atlanta, GA
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2018 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Closed access
EKEun-Ju Ko
Eun-Ju Ko
SKSang-Moo Kang
Sang-Moo Kang
Adjuvants are included in vaccine formulations to enhance the immunogenicity and efficacy of vaccines. MF59® is an oil-in-water emulsion adjuvant and licensed for use in pandemic and seasonal influenza vaccines in many countries. MF59 is safe and well tolerated in humans. MF59-adjuvanted vaccination spares vaccine dose and enhances hemagglutination inhibiting antibodies against homologous and heterologous influenza virus strains. The mechanisms of MF59 involve rapid induction of chemokines, inflammatory cytokines, recruiting multiple immune cells, uric acid and benign apoptosis of certain innate immune cells. The adjuvant effects of MF59 on generating vaccine-specific isotype-switched IgG antibodies, effector CD8 T cells, and protective immunity were retained even in a CD4-deficient condition by inducing effective immune-competent microenvironment with various innate and antigen presenting cells in a mouse model. CD4-independent adjuvant effects of MF59 might contribute to improving the vaccine efficacy in children, the elderly, and immunocompromised patients as well as in healthy adults. Further studies will be needed to broaden the use of MF59 in various vaccine antigens and populations as well as lead to better understanding of the action mechanisms of MF59 adjuvant.

4 October 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MPMin-Kyung Park
Min-Kyung Park
VNVu Ngo
Vu Ngo
YKYoung-Man Kwon
Young-Man Kwon
YLYoung-Tae Lee
Young-Tae Lee
SYSieun Yoo
Sieun Yoo
SKSang-Moo Kang
Sang-Moo Kang
Lactobacillus plantarum DK119 (DK119) isolated from the fermented Korean cabbage food was used as a probiotic to determine its antiviral effects on influenza virus. DK119 intranasal or oral administration conferred 100% protection against subsequent lethal infection with influenza A viruses, prevented significant weight loss, and lowered lung viral loads in a mouse model. The antiviral protective efficacy was observed in a dose and route dependent manner of DK119 administration. Mice that were treated with DK119 showed high levels of cytokines IL-12 and IFN-γ in bronchoalveolar lavage fluids, and a low degree of inflammation upon infection with influenza virus. Depletion of alveolar macrophage cells in lungs and bronchoalveolar lavages completely abrogated the DK119-mediated protection. Modulating host innate immunity of dendritic and macrophage cells, and cytokine production pattern appeared to be possible mechanisms by which DK119 exhibited antiviral effects on influenza virus infection. These results indicate that DK119 can be developed as a beneficial antiviral probiotic microorganism.

1 February 2013 in Molecular Therapy
Verified
Journal Article
Open access
MKMin-Chul Kim
Min-Chul Kim
JSJae-Min Song
Jae-Min Song
OEO Eunju
O Eunju
YKYoung-Man Kwon
Young-Man Kwon
YLYoun-Jeong Lee
Youn-Jeong Lee
SKSang-Moo Kang
Sang-Moo Kang
The extracellular domain of M2 (M2e), a small ion channel membrane protein, is well conserved among different human influenza A virus strains. To improve the protective efficacy of M2e vaccines, we genetically engineered a tandem repeat of M2e epitope sequences (M2e5x) of human, swine, and avian origin influenza A viruses, which was expressed in a membrane-anchored form and incorporated in virus-like particles (VLPs). The M2e5x protein with the transmembrane domain of hemagglutinin (HA) was effectively incorporated into VLPs at a several 100-fold higher level than that on influenza virions. Intramuscular immunization with M2e5x VLP vaccines was highly effective in inducing M2e-specific antibodies reactive to different influenza viruses, mucosal and systemic immune responses, and cross-protection regardless of influenza virus subtypes in the absence of adjuvant. Importantly, immune sera were found to be sufficient for conferring protection in naive mice, which was long-lived and cross-protective. Thus, molecular designing and presenting M2e immunogens on VLPs provide a promising platform for developing universal influenza vaccines without using adjuvants.

1 January 2014 in Clinical and Experimental Vaccine Research
Verified
Journal Article
Open access
PDF file
YLYoung-Tae Lee
Young-Tae Lee
KKKi-Hye Kim
Ki-Hye Kim
EKEun-Ju Ko
Eun-Ju Ko
YLYu-Na Lee
Yu-Na Lee
MKMin-Chul Kim
Min-Chul Kim
SKSang-Moo Kang
Sang-Moo Kang
Lee YT, et al. Clin Exp Vaccine Res. 2014 Jan;3(1):12-28. https://doi.org/10.7774/cevr.2014.3.1.12

12 December 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YJYu-Jin Jung
Yu-Jin Jung
YLYoung-Tae Lee
Young-Tae Lee
VNVu Le Ngo
Vu Le Ngo
YCYoung-Hee Cho
Young-Hee Cho
EKEun-Ju Ko
Eun-Ju Ko
SKSang-Moo Kang
Sang-Moo Kang
Lactic acid bacteria (LAB) are the common probiotics. Here, we investigated the antiviral protective effects of heat-killed LAB strain Lactobacillus casei DK128 (DK128) on influenza viruses. Intranasal treatment of mice with DK128 conferred protection against different subtypes of influenza viruses by lessening weight loss and lowering viral loads. Protection via heat-killed DK128 was correlated with an increase in alveolar macrophage cells in the lungs and airways, early induction of virus specific antibodies, reduced levels of pro-inflammatory cytokines and innate immune cells. Importantly, the mice that were protected against primary viral infection as a result of heat-killed DK128 pretreatment developed subsequent heterosubtypic immunity against secondary virus infection. For protection against influenza virus via heat-killed DK128 pretreatment, B cells and partially CD4 T cells but not CD8 T cells were required as inferred from studies using knockout mouse models. Our study provides insight into how hosts can be equipped with innate and adaptive immunity via heat-killed DK128 treatment to protect against influenza virus, supporting that heat-killed LAB may be developed as anti-virus probiotics.

1 August 2012 in Expert Review of Vaccines
Verified
Journal Article
Closed access
SKSang-Moo Kang
Sang-Moo Kang
MKMin-Chul Kim
Min-Chul Kim
RCRichard W Compans
Richard W Compans
Current influenza vaccines are primarily targeted to induce immunity to the influenza virus strain-specific hemagglutinin antigen and are not effective in controlling outbreaks of new pandemic viru...